Current news
TPC Researchers Present at the SPHN Data for Health Symposium
Prof. Bernd Bodenmiller and Prof. Dr. Andreas Wicki Presented the Swiss Personalized Oncology National Data Streams Project (SPO-NDS) at the Swiss Personalized Health Network (SPHN) "Data for Health" Symposium held on October 31st in Bern. The Symposium highlighted efforts by the SPHN and PHRT to establish coordinated data infrastructures to make health data more accessible and useful for research and clinical collaborations across Switzerland. To find out more about the Symposium, click on the link!
SPHN Data for Health Symposium
To find out more about the SPO-NDS Project, use the link below!
TPC Researchers Publish Findings from TuPro Study in Nature Communications
The TPC is proud to announce the publication of results from one cohort in the TuPro Study. Researchers lead by Alexandre Theocharides published findings related to the AML cohort in Nature Communications on October 30th. The publication describes results from combining single-cell multi-omics and functional profiling for AML patients to show mechanisms of drug resistance and identify areas of emerging treatment resistance. Please follow the link to the article to read more!
Medicine @ ETH Day
The Medicine @ ETH Day event held in the Fall of 2024 was designed to facilitate networking and the exchange of ideas across all players in the field of medical research.
TPC Participates in Future Health Basel 2024
The TPC was able to participate in the Swiss-wide Health Conference, Future Health Basel. Future Health is nation wide conference, with a focus on addressing the challenges facing the Swiss healthcare system with presentations and participation from national and international healthcare innovators.
Tumor Profiler Center scientists describe strategy to target persister cancer cells
Therapeutic resistance in cancer treatment can be divided into primary resistance (lack of response to initial therapy due to preexisting genetic mutations) and acquired resistance (relapse despite initial response, caused by intratumor heterogeneity and other factors). While genetic alterations are known to contribute to acquired resistance, recent evidence suggests the involvement of non-genetic adaptive mechanisms.
Bernd Bodenmiller presents TPC at the Life Science Zurich Impact Conference DATA FOR HEALTH
@BodenmillerLab Precision Oncology keynote lecture
at the Life Science Zurich Impact Conference DATA FOR HEALTH 23 May 2023, at the Technopark Zurich.